Literature DB >> 14557960

Attributable mortality of nosocomial candidemia, revisited.

Olafur Gudlaugsson1, Shane Gillespie, Kathleen Lee, Jeff Vande Berg, Jianfang Hu, Shawn Messer, Loreen Herwaldt, Michael Pfaller, Daniel Diekema.   

Abstract

We reexamined the attributable mortality of nosocomial candidemia 15 years after a retrospective cohort study performed at our hospital demonstrated an attributable mortality of 38%. For all episodes of nosocomial candidemia between 1 July 1997 and 30 June 2001, we matched control patients with case patients by age, sex, date of hospital admission, underlying disease(s), length of time at risk, and surgical procedure(s). We analyzed 108 matched pairs. There were no statistically significant differences in age, sex, underlying disease(s), time at risk, surgical procedure, or vital signs at admission between cases and controls. The crude mortality among case patients was 61% (66 of 108 patients), compared with 12% (13 of 108) among control patients, for an attributable mortality of 49% (95% CI, 38%-60%). Nosocomial candidemia is still associated with an extremely high crude and attributable mortality--much higher than that expected from underlying disease alone.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14557960     DOI: 10.1086/378745

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  372 in total

Review 1.  Human genetic susceptibility to Candida infections.

Authors:  Theo S Plantinga; Melissa D Johnson; William K Scott; Leo A B Joosten; Jos W M van der Meer; John R Perfect; Bart Jan Kullberg; Mihai G Netea
Journal:  Med Mycol       Date:  2012-06-04       Impact factor: 4.076

2.  Increased susceptibility to Candida infection following cecal ligation and puncture.

Authors:  Christopher G Davis; Kathy Chang; Dale Osborne; Andrew H Walton; W Michael Dunne; Jared T Muenzer
Journal:  Biochem Biophys Res Commun       Date:  2011-09-12       Impact factor: 3.575

3.  Caspofungin activity against clinical isolates of fluconazole-resistant Candida.

Authors:  Michael A Pfaller; Shawn A Messer; Linda Boyken; Cassie Rice; Shailesh Tendolkar; Richard J Hollis; Daniel J Diekema
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

Review 4.  Prophylaxis and treatment of invasive candidiasis in the intensive care setting.

Authors:  L Ostrosky-Zeichner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-10       Impact factor: 3.267

Review 5.  Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

6.  Canadian clinical practice guidelines for invasive candidiasis in adults.

Authors:  Eric J Bow; Gerald Evans; Jeff Fuller; Michel Laverdière; Coleman Rotstein; Robert Rennie; Stephen D Shafran; Don Sheppard; Sylvie Carle; Peter Phillips; Donald C Vinh
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

7.  Residual attributable mortality, a new concept for understanding the value of antibiotics in treating life-threatening acute infections.

Authors:  Richard P Wenzel; Chris Gennings
Journal:  Antimicrob Agents Chemother       Date:  2010-09-20       Impact factor: 5.191

8.  Yeast and Filaments Have Specialized, Independent Activities in a Zebrafish Model of Candida albicans Infection.

Authors:  Brittany G Seman; Jessica L Moore; Allison K Scherer; Bailey A Blair; Sony Manandhar; Joshua M Jones; Robert T Wheeler
Journal:  Infect Immun       Date:  2018-09-21       Impact factor: 3.441

9.  Candida albicans flu1-mediated efflux of salivary histatin 5 reduces its cytosolic concentration and fungicidal activity.

Authors:  Rui Li; Rohitashw Kumar; Swetha Tati; Sumant Puri; Mira Edgerton
Journal:  Antimicrob Agents Chemother       Date:  2013-02-04       Impact factor: 5.191

10.  Shear stress modulates the thickness and architecture of Candida albicans biofilms in a phase-dependent manner.

Authors:  Pranab K Mukherjee; David V Chand; Jyotsna Chandra; James M Anderson; Mahmoud A Ghannoum
Journal:  Mycoses       Date:  2008-12-09       Impact factor: 4.377

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.